Summary: Two poster presentations showing AFM24 as a monotherapy and combination treatment will be presented
Summary: Affimed has generated an impressive pipeline of innate cell engagers programs created using their
Summary: Affimed experienced a four-month-long sell-off but has caught a bid following their full-year 2021
Summary: Affimed reported mixed Q2 earnings that revealed more milestone payments from their partnerships. In
Summary: Affimed recently reported their Q1 earnings that revealed a solid beat on EPS and